BioWorld

July 11, 2011

View Archived Issues

BioLineRx Trades IPO for ADR To Access Investors, Partners

New Fentanyl Approvals Hint At Track for Class-Wide REMS

Money Raised By Biotech in 2011

Week in Review

Word on the Street

FDA Approvals in June

Phase I Clinical Trials Update: June 2011

Phase II Clinical Trials Update: June 2011

Phase III Clinical Trials Update: June 2011

American Diabetes Association

American Society of Clinical Oncology

Public Biotechs Drive Funding Increase in H1 2011 v. H1 2010

Biotech companies raised a total of $13.3 billion in the first half of 2011, reclaiming much of the fundraising ground that was lost when the markets crashed in 2008. Read More

Money Raised Year to Date

Non-U.S. Clinical Trials & Regulatory Actions: June 2011

FDA Submissions, Approvals & Other Actions: June 2011

Stock Gainers and Losers For The Week

BioWorld Stock Report For Public Biotechnology Companies

Today's news in brief

BioWorld

IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa

BioWorld Science

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...

TL1A is overexpressed in hidradenitis suppurativa

BioWorld Science

Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...

Illustration of head with maze that is missing parts

Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke

BioWorld Science

Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...

VST Bio’s VB-001 is neuroprotector after stroke

BioWorld Science

At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...